MXPA05013460A - Compuestos de n-{piperazina '4-sustituida-1-sulfonilmetil-alquil}-n-hidroxiformamida como inhibidores de metaloproteinasas. - Google Patents

Compuestos de n-{piperazina '4-sustituida-1-sulfonilmetil-alquil}-n-hidroxiformamida como inhibidores de metaloproteinasas.

Info

Publication number
MXPA05013460A
MXPA05013460A MXPA05013460A MXPA05013460A MXPA05013460A MX PA05013460 A MXPA05013460 A MX PA05013460A MX PA05013460 A MXPA05013460 A MX PA05013460A MX PA05013460 A MXPA05013460 A MX PA05013460A MX PA05013460 A MXPA05013460 A MX PA05013460A
Authority
MX
Mexico
Prior art keywords
alkyl
ring
aryl
hydroxyfomamide
aco4
Prior art date
Application number
MXPA05013460A
Other languages
English (en)
Spanish (es)
Inventor
Maurice Raymond Verscho Finlay
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05013460(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA05013460A publication Critical patent/MXPA05013460A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA05013460A 2003-06-27 2004-06-23 Compuestos de n-{piperazina '4-sustituida-1-sulfonilmetil-alquil}-n-hidroxiformamida como inhibidores de metaloproteinasas. MXPA05013460A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds
PCT/GB2004/002702 WO2005000822A1 (en) 2003-06-27 2004-06-23 N-{‘4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
MXPA05013460A true MXPA05013460A (es) 2006-03-09

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013460A MXPA05013460A (es) 2003-06-27 2004-06-23 Compuestos de n-{piperazina '4-sustituida-1-sulfonilmetil-alquil}-n-hidroxiformamida como inhibidores de metaloproteinasas.

Country Status (33)

Country Link
US (1) US7485644B2 (cg-RX-API-DMAC7.html)
EP (1) EP1644340B1 (cg-RX-API-DMAC7.html)
JP (1) JP4701167B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060026440A (cg-RX-API-DMAC7.html)
CN (2) CN102229589A (cg-RX-API-DMAC7.html)
AR (1) AR044931A1 (cg-RX-API-DMAC7.html)
AT (1) ATE414063T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004251104B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0411929A (cg-RX-API-DMAC7.html)
CA (1) CA2529468A1 (cg-RX-API-DMAC7.html)
CO (1) CO5650254A2 (cg-RX-API-DMAC7.html)
CY (1) CY1108757T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004017733D1 (cg-RX-API-DMAC7.html)
DK (1) DK1644340T3 (cg-RX-API-DMAC7.html)
ES (1) ES2315675T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20090009T3 (cg-RX-API-DMAC7.html)
IL (1) IL172615A0 (cg-RX-API-DMAC7.html)
IS (1) IS8257A (cg-RX-API-DMAC7.html)
MX (1) MXPA05013460A (cg-RX-API-DMAC7.html)
MY (1) MY138680A (cg-RX-API-DMAC7.html)
NO (1) NO20060444L (cg-RX-API-DMAC7.html)
NZ (1) NZ544208A (cg-RX-API-DMAC7.html)
PL (1) PL1644340T3 (cg-RX-API-DMAC7.html)
PT (1) PT1644340E (cg-RX-API-DMAC7.html)
RU (1) RU2351595C2 (cg-RX-API-DMAC7.html)
SA (1) SA04250224B1 (cg-RX-API-DMAC7.html)
SE (1) SE0301922D0 (cg-RX-API-DMAC7.html)
SI (1) SI1644340T1 (cg-RX-API-DMAC7.html)
TW (1) TW200524898A (cg-RX-API-DMAC7.html)
UA (1) UA81491C2 (cg-RX-API-DMAC7.html)
UY (1) UY28387A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005000822A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200510458B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
AU2006307939B2 (en) * 2005-10-26 2012-03-29 Merck Serono Sa Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8765814B2 (en) * 2010-07-08 2014-07-01 Kaken Pharmaceutical Co., Ltd. N-hydroxyformamide derivative and medicament containing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69934094T2 (de) * 1998-01-30 2007-06-06 Darwin Discovery Ltd., Slough N-hydroxyformamid-derivate
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
ES2281346T3 (es) * 1999-06-04 2007-10-01 Astrazeneca Ab Inhibidores de metaloproteinasas.
EP1261590B1 (en) 2000-02-21 2012-04-11 AstraZeneca AB Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
CA2483314A1 (en) * 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
DE602004017178D1 (de) * 2003-06-19 2008-11-27 Ucb Pharma Sa Hydroxamatsulfonamide als inhibitoren von cd23-shedding

Also Published As

Publication number Publication date
EP1644340A1 (en) 2006-04-12
CN1812974A (zh) 2006-08-02
CA2529468A1 (en) 2005-01-06
SI1644340T1 (sl) 2009-02-28
IS8257A (is) 2006-01-23
DK1644340T3 (da) 2009-02-02
JP4701167B2 (ja) 2011-06-15
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
DE602004017733D1 (de) 2008-12-24
MY138680A (en) 2009-07-31
WO2005000822A1 (en) 2005-01-06
SE0301922D0 (sv) 2003-06-27
HK1086835A1 (en) 2006-09-29
AR044931A1 (es) 2005-10-12
AU2004251104A1 (en) 2005-01-06
ATE414063T1 (de) 2008-11-15
US20070197542A1 (en) 2007-08-23
AU2004251104B2 (en) 2008-05-08
IL172615A0 (en) 2006-04-10
PL1644340T3 (pl) 2009-04-30
US7485644B2 (en) 2009-02-03
NO20060444L (no) 2006-03-22
ZA200510458B (en) 2007-03-28
JP2007516164A (ja) 2007-06-21
CN102229589A (zh) 2011-11-02
CY1108757T1 (el) 2014-04-09
TW200524898A (en) 2005-08-01
RU2005141058A (ru) 2006-07-27
KR20060026440A (ko) 2006-03-23
HRP20090009T3 (en) 2009-02-28
BRPI0411929A (pt) 2006-08-15
RU2351595C2 (ru) 2009-04-10
EP1644340B1 (en) 2008-11-12
ES2315675T3 (es) 2009-04-01
CO5650254A2 (es) 2006-06-30
UY28387A1 (es) 2005-01-31
CN1812974B (zh) 2011-06-29
PT1644340E (pt) 2009-01-02
UA81491C2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
MXPA05007496A (es) Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes.
NO20055568L (no) Substituerte 1,4-diazepiner og anvendelser derav
HRP20050830A2 (en) Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
SE9703377D0 (sv) New compounds
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
MXPA05009660A (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol.
IL148875A0 (en) Sulfonyl hydrazide derivatives, their preparation and pharmaceutical compositions containing them
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
MXPA05007563A (es) Inhibidores de la integrasa del vih, composiciones farmaceuticas y metodos para su uso.
TNSN07395A1 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
CY1108757T1 (el) Ενωσεις ν-{'4-υποκατεστημενη πιπεραζινη-1-σουλφονυλμεθυλαλκυλ}-ν-υδροξυφορμαμιδιου ως αναστολεις της μεταλλοπρωτεϊνασης.
NO20060383L (no) Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister
HUP0204501A2 (hu) Gyűrűs vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint eljárás a vegyületek előállítására és alkalmazásuk
AR021968A1 (es) Oximas e hidrazonas sustituidas como antagonistas de neuroquinina
EA200101204A1 (ru) Новые бициклические соединения аминопиразинона, способ их получения и содержащие их фармацевтические композиции
RU2013103726A (ru) Риминофеназины, замещенные 2-(гетероарил)аминогруппами, и их противомикробное действие
EA200500683A1 (ru) Новые соединения пирролидина и тиазолидина, способ их получения и фармацевтические композиции, которые их содержат
AR040565A1 (es) Derivados de 3- guanidocarbonil 1-heteroaril - indol, procedimiento de preparacion, su uso como medicamentos y composiciones farmaceuticas que los contienen
EA200001248A1 (ru) Новые линейные и циклические производные мочевины, способ их получения и их содержащие фармацевтические композиции
AR038967A1 (es) Derivados de 2,3 - diaril - pirazolidinas como inhibidores de enzimas que degradan la neurotensina
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат

Legal Events

Date Code Title Description
FG Grant or registration